InMode (INMD) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
27 Dec, 2025Executive summary
Q1 2025 revenue was $77.9 million, down 3% year-over-year, with gross margin at 78% GAAP and 79% non-GAAP, both slightly lower than last year.
U.S. market share declined to 50% of revenue, with international sales rising to 49%, led by record performance in Europe despite macroeconomic headwinds.
GAAP net income was $18.2M ($0.26/diluted share), non-GAAP net income was $21.4M ($0.31/diluted share), both down from Q1 2024.
The company maintained its workforce and continued investing in R&D and sales, expecting to benefit when demand rebounds.
Completed a 6.95M share repurchase in April 2025, returning $127M to shareholders; $412M returned over 12 months, about 27% of share capital.
Financial highlights
Q1 2025 revenue was $77.9M, with non-GAAP net income of $21.4M and non-GAAP diluted EPS of $0.31.
GAAP gross margin was 78% (down from 80%); non-GAAP gross margin was 79%.
GAAP operating margin was 20% (down from 23%); non-GAAP operating margin was 23% (down from 27%).
Cash, equivalents, and short-term investments totaled $512.9M as of March 31, 2025.
Installed base: 12,054 units in the US, 27,884 units worldwide.
Outlook and guidance
2025 revenue guidance is $395–$405 million, with non-GAAP gross margin of 78–80% (previously 80–82%).
Non-GAAP operating income guidance is $101–$106 million (previously $130–$135 million).
Non-GAAP EPS guidance is $1.64–$1.68 (previously $1.95–$1.99).
Guidance assumes Q2 will be seasonally stronger; if not, guidance may be revised downward.
Management expects U.S. market headwinds and 2–3% gross margin impact from tariffs to persist through year-end.
Latest events from InMode
- Growth from new products offsets margin pressure; global expansion and R&D drive future potential.INMD
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - Manufacturing and logistics face disruption, but strategic buybacks and global expansion continue.INMD
Oppenheimer 36th Annual Healthcare MedTech & Services Conference16 Mar 2026 - Flat top line expected in 2026, with new products and restructuring to drive future recovery.INMD
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Q4 revenue up 6% to $103.9M, FY sales down 6%, 2026 stable with new launches and strong cash.INMD
Q4 202510 Feb 2026 - Q2 revenue fell 36.5% to $86.4M; guidance cut, but new launches and buybacks support outlook.INMD
Q2 20242 Feb 2026 - Strong innovation and global expansion offset U.S. softness; M&A remains top capital priority.INMD
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Product refresh, robust margins, and innovation drive growth amid macro headwinds and financing shifts.INMD
Jefferies Global Healthcare Conference31 Jan 2026 - 2024 buyback, international expansion, and new product upgrades drive long-term growth focus.INMD
Baird's 2024 Global Healthcare Conference21 Jan 2026 - Q3 2024 revenue rose to $130.2M, but margins and guidance declined amid macro headwinds.INMD
Q3 202417 Jan 2026 - Stable but soft market, ongoing investment, and new segments drive future growth opportunities.INMD
UBS Global Healthcare Conference 202414 Jan 2026